Roland Goette sold $1.1M of BDX
EVP and President, EMEA at BECTON DICKINSON & CO. 5,121 shares at an average of $220.76, traded Dec 6, 2024, filed Dec 10, 2024.
Score components
- +15RoleOfficer
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-24-020404, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 6, 2024 | MOption exercise Common Stock10b5-1 | +6,995 | $147.68 | $1.0M | 22,489 | Dec 10, 2024 |
| Dec 6, 2024 | MOption exercise Common Stock10b5-1 | +6,339 | $167.91 | $1.1M | 28,828 | Dec 10, 2024 |
| Dec 6, 2024 | SOpen-market sale Common Stock10b5-1 | -4,483 | $221.01 | $991k | 24,345 | Dec 10, 2024 |
| Dec 6, 2024 | DDisposition to issuer Common Stock10b5-1 | -9,490 | $221.01 | $2.1M | 14,855 | Dec 10, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stock10b5-1 | -638 | $219.03 | $140k | 14,217 | Dec 10, 2024 |
| Dec 6, 2024 | MOption exercise Stock Appreciation Rightsderivative10b5-1 | -6,995 | $0.00 | $0 | 0 | Dec 10, 2024 |
| Dec 6, 2024 | MOption exercise Stock Appreciation Rightsderivative10b5-1 | -6,339 | $0.00 | $0 | 0 | Dec 10, 2024 |
Related signals
Other insiders at BECTON DICKINSON & CO and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP, Chief Revenue Officer | $14k 76 shares | -0% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP, CRO & Pres. Life Sciences | $15k 74 shares | -0% | |
| 13Weak | BECTON DICKINSON & CO | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | $123k 629 shares | -5% | |
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP, CRO & Pres. Life Sciences | $15k 75 shares | -0% | |
| 29Weak | BECTON DICKINSON & CO | Bertram L Scott director | $38k 217 shares | -1% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $11k 57 shares | -1% | |
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $10k 58 shares | -1% | |
| 26Weak | BDXsell BECTON DICKINSON & CO | Claire Fraser director | $172k 917 shares | -4% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $11k 57 shares | -1% | |
| 54Moderate | BDXbuy BECTON DICKINSON & CO | Gregory Hayes director | $1.0M 5,250 shares | +660% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.